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THE BIGGER PICTURE This study is based on the premise that combining information from multiple layers
of data can result in new biologically interpretable associations in several ways. The underlying and unifying
theme of this study is data integration, data mining, and meta-analysis for pattern detection that supports
knowledge discovery and generation of hypotheses. The methods and the workflow used are disease
agnostic and can be applied to any disease or phenotype that has multiple models and heterogeneous
data elements. By integrating and joint analysis of several heterogeneous data types (multiple disease
models, viral-host protein interaction data, single-cell RNA-sequencing data, protein-protein interactions,
and genome-wide association study data), gene functional modules are identified that can have direct
bearing on furthering the understanding of COVID-19.

Development/Pre-production: Data science output has been
rolled out/validated across multiple domains/problems

SUMMARY

Standard transcriptomic analyses alone have limited power in capturing the molecular mechanisms driving
disease pathophysiology and outcomes. To overcome this, unsupervised network analyses are used to identify clusters of genes that can be associated with distinct molecular mechanisms and outcomes for a disease.
In this study, we developed an integrated network analysis framework that integrates transcriptional signatures from multiple model systems with protein-protein interaction data to find gene modules. Through a
meta-analysis of different enriched features from these gene modules, we extract communities of highly interconnected features. These clusters of higher-order features, working as a multifeatured machine, enable
collective assessment of their contribution for disease or phenotype characterization. We show the utility of
this workflow using transcriptomics data from three different models of SARS-CoV-2 infection and identify
several pathways and biological processes that could enable understanding or hypothesizing molecular signatures inducing pathophysiological changes, risks, or sequelae of COVID-19.

INTRODUCTION
In vitro and in vivo disease models often fail to completely recapitulate the disease manifestations in humans. Integrated secondary analysis approaches that can identify disease-related
gene modules by leveraging knowledge from multiple disease
models can find physiological functions in a disease. Functional
complexes that arise out of these gene or protein modules are
known to represent distinct biological functions.1,2 Similarly,

feature networks comprising biological processes, pathways,
phenotypes, and cell types represent a higher-order multifeatured machines collectively working toward a common goal.
Based on this premise, we implemented a multilayered datamining methodology that leverages protein modules to build
functional modules or complexes in a disease. These functional
complexes are built by linking together several heterogeneous
data types such as single-cell RNA-sequencing (RNA-seq)
markers, protein-protein interactions, and phenotype-genotype
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associations. To demonstrate the utility of this joint analysis
approach, we analyzed transcriptomic data from two in vitro
models (Calu-3 and Vero E6 cells) and one in vivo model (Ad5hACE2-sensitized mice) of SARS-CoV-2 infection.
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV2, has affected more than 75 million people with more than 1.6
million deaths worldwide including 17.3 million confirmed infections and >311,000 deaths in the United States (World Health
Organization, December 20, 2020). The limited and emerging
stages of data and information surrounding this disease, and
the necessity to find effective interventions (e.g., vaccines, small
molecules), provides a strong rationale for a multilayered, secondary analysis of existing data collected from different models
and studies. Some of the noteworthy discoveries surrounding
SARS-CoV-2 are direct offshoots of secondary data analysis using available omics data generated in pre-COVID-19 times.
These existing data include single-cell RNA-seq (scRNA-seq)
data3,4 from the Human Cell Atlas consortium or eQTL variant
data5 from the Genotype Tissue Expression (GTEx) database.6
Thus, leveraging the available repository of datasets and information, even if they were not designed specifically to study
COVID-19, can provide a jump start to discover different sides
of this disease. Recently there have been several studies reporting network analysis-based approaches applied to both COVID19- and non-COVID-19-related data to detect tissue-specific7,8
or pan-tissue9 networks of interacting genes specific to SARSCoV-2 infections. These studies differ in the input ‘‘seed’’ genes
used to construct the networks; some studies are focused on the
SARS-CoV-2 entry-associated receptors and/or proteases7,9
while the others use an expanded set of virus-host interactants
in SARS-CoV-2.8,10 However, most of these methods do not
consider the differentially expressed genes (DEGs) in the host
following the SARS-CoV-2 infection in their analysis. A recently
published study11 used differentially expressed host genes in
SARS-CoV-2-infected bronchial epithelial cells (NHBE) along
with the SARS-CoV-2 entry receptor ACE2 and SARS-CoV-2 entry-associated protease TMPRSS2 to construct a host gene regulatory network. This study, however, is based on a single SARSCoV-2 infection model with a limited set (three samples) of
SARS-CoV-2 infection samples. Additionally, the study did not
consider other host-virus interactants specific to SARS-CoV-2
virus. To overcome these limitations and address some of these
issues, we used transcriptomic data from three model systems
(two in vitro and one in vivo) of SARS-CoV-2 infection, SARSCoV-2 viral-host protein interaction data, and analyzed them
jointly with non-COVID-19/SARS-CoV-2 data. For the latter, we
used the scRNA-seq markers from three human lung studies,
protein-protein interactions, and genome-wide association
study (GWAS) data (Figure 1). While we acknowledge the
complexity of SARS-CoV-2 infection, we believe that our study
supports knowledge discovery and formulation of testable hypotheses for COVID-19 pathogenesis.
RESULTS
Consensus transcriptome in SARS-CoV-2 infection
The pathophysiology of most viral infections is associated with
host protein complexes, which are manipulated to hijack the individual cell biological processes. Therefore, to evaluate this
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phenomenon, we first built an interactome around the
consensus transcriptome of SARS-CoV-2 infection. To obtain
a consensus transcriptomic signature, we considered DEGs in
at least two of the three SARS-CoV-2 models12–14 compared
(i.e., two cell lines, namely, transformed lung-derived Calu-3
cells and VeroE6 cells, and a mouse model) (Figure 2A and Table
1). A strong concordance was seen among the upregulated and
downregulated gene signatures from the three models. A total of
732 DEGs (537 upregulated and 195 downregulated) were
shared between the SARS-CoV-2-infected human Calu-3 and
non-human primate VeroE6 cell lines (Figure 2B). Similarly, we
found 325 upregulated and 369 downregulated genes common
between the Calu-3 model and Ad5-hACE2-sensitized mice.
While there was an overall concordance among the DEGs,
each of the three models also had several DEGs unique to
them (Figure 2C and Table S1). We further validated these
DEGs by comparing them with a transcriptomic signature from
COVID-19 patients (GEO: GSE152075; nasopharyngeal swabs
from 430 patients and 54 controls).15 There was a stronger
concordance with the transcriptomic signature from the Calu-3
and the Ad5-hACE2-sensitized mouse model systems than the
one from the VeroE6 cell line model (Figure S1). Finally, a total
of 1,467 consensus genes (833 upregulated and 634 downregulated) were found (Figure 2C and Table S2) from the three disease models. This included 106 genes upregulated and 41 genes
downregulated in all three model systems (Figures 2C and 2D),
representing the ‘‘core’’ dysregulated transcriptome in SARSCoV-2 infection. Both these sets of consensus signatures were
enriched for several functional terms (Tables S3, S4, and S5)
and human lung cell-type markers (Table S6 and Figure S2).
Additionally, these gene sets were also enriched for several
physiological and pathological traits (from the Phenotype-Genotype Integrator [PheGenI]16 and GWAS catalog17 databases) (Tables S7 and S8; Figure S3).
Interactome of consensus transcriptome of SARS-CoV2 infection and virus-host protein-protein interactions
To build a consensus SARS-CoV-2 interactome, we used the
SARS-CoV-2-human virus-host protein-protein interaction
(PPI) dataset comprising 332 human proteins involved in assembly and trafficking of RNA.18 These are in addition to the
SARS-CoV-2 entry receptor ACE2, and SARS-CoV-2 entryassociated proteases, namely, TMPRSS2, CTSB, and CTSL.
More than half (151 genes) of these 336 SARS-CoV-2-human
interacting proteins were differentially expressed in at least
one of the three model systems (Figure 3A). Of these, 29 genes
(16 upregulated and 13 downregulated) were part of the
consensus signature.
Using the disease consensus transcriptomic signature and
the SARS-CoV-2-proteome interacting human proteins as an
input, we queried the STRING (v11) database19 and generated
a DEG-PPI integrated network. Only the interactions with highest confidence score (0.9) or experimental interaction score of
0.7 or more in STRING were used. We observed an enrichment
for PPIs (p < 1.0 3 10 16) among the combined gene set (Figure 3B). In other words, this combined set of SARS-CoV-2
consensus signature and SARS-CoV-2-human interaction
map have significantly more interactions among themselves
than would be expected for a random set of proteins of similar
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Figure 1. Schematic representation of the
workflow
Transcriptomic data from three SARS-CoV-2
infection models are processed to identify differentially expressed genes (DEGs). Genes that are upor downregulated in two out of three models are
considered as ‘‘consensus signature.’’ The
consensus DEGs, along with the SARS-CoV-2-human virus-host interactome, are used to build an
integrated network based on known protein-protein
interactions (PPIs) retrieved from STRING database
(v11). A Markov clustering (MCL) algorithm is then
used to identify modules of highly interconnected
genes from this integrated interactome. These gene
modules are characterized through functional enrichments (pathways, biological processes), lung
single-cell markers, and phenotypic trait (genomewide association [GWA]) loci. In the final step, an
enriched feature network is constructed using all the
enriched terms and features from the modules to
extract functional complexes or communities of
highly interconnected features.

genes. These 35 clusters were made up
of a total of 797 genes of which 627
were consensus DEGs in SARS-CoV-2
infection models (see Figures 3C–3H for
six example clusters and Table S9 for
more details). Of the 35 clusters, 29 clusters had at least one gene-encoding protein that interacts with the SARS-CoV-2
proteome. We hypothesize that these
SARS-CoV-2-targeted human protein
clusters are informative in deciphering
the COVID-19 pathophysiology and inferring the function of the SARS-CoV-2 targets based on other members in the protein clusters.

size drawn from the genome. We next identified network clusters from this joint interactome using a Markov clustering (MCL)
algorithm. In brief, MCL clusters a network to determine modules of genes with more intramodular (within the module) than
intermodular (with other modules) interactions. Each gene can
only be assigned to a single module through this method.
The inflation factor parameter determines the granularity (or
‘‘tightness’’) of the clusters and thereby the cluster size. In all
our experiments with SARS-CoV-2 infection models, we used
the default inflation parameter (2.5). With MCL clustering, we
found 153 clusters of varying gene counts (Table S9). We
selected 35 candidate clusters with each having at least five

Characterization of SARS-CoV-2targeted human protein modules
Gene clusters: Functional
enrichment
The next step in our multilayered
approach was to obtain enriched biological processes and pathways for the identified gene modules (Table S10). Cluster
C-1 (190 genes) was enriched for innate
immune response (48 genes) and type I interferon signaling
(26 genes) while genes from cluster C-2 (92 genes) were
involved in transport regulation (31 genes) and tube development (31 genes). We also found genes associated with
abnormal cardiovascular development (21 genes) in cluster C2. Clusters C-7 (20 genes) and C-8 (20 genes) had genes associated with abnormal interleukin and cytokine secretion phenotypes. Clusters C-12 (14 genes), C-28 (6 genes), and C-23 (8
genes) were all enriched for mitochondrion translation, organization, and transport. Finally, several genes regulating circadian
rhythm in mammals (NFIL3, PER1, PER2, PER3, and SIK1)
were seen in cluster C-25 (7 genes).
Patterns 2, 100247, May 14, 2021 3
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Figure 2. Transcriptomic overlaps among the two in vitro and one in vivo SARS-CoV-2 infection models
(A) Network of DEGs from the three SARS-CoV-2 infection models (Calu-3, VeroE6, and Ad5-hACE2 mice). The orange- and navy-blue-colored nodes are genes
upregulated or downregulated, respectively, in at least two models. The red- and green-colored nodes are genes that are up- or downregulated in all the models
compared.
(B) Heatmap indicating the transcriptomic overlaps between the different SARS-CoV-2 infection models. The size and significance of the overlaps is measured
using the gene counts and Fisher’s exact test, respectively.
(C) Venn diagram showing comparison of the up- or downregulated DEGs in the three models.
(D) List of the ‘‘core’’ upregulated (106 genes, red font) and downregulated (41 genes, green font) genes in all the three model systems.
(E and F) Network representation of enriched biological processes and pathways in the core upregulated (E) or downregulated (F) genes from the SARS-CoV-2
infection models. Orange- and purple-colored nodes are genes up- or downregulated, respectively. The different colored rectangles are enriched biological
processes and pathways. Enrichment analysis was done using the ToppFun application of the ToppGene Suite, and network was generated using the Cytoscape
application.

Gene clusters: Lung single-cell markers
We next evaluated the candidate gene modules for lung singlecell associations by performing enrichment analysis of the
modules against single-cell marker gene sets compiled from
three different human lung scRNA-seq studies.20–22 Of the 35
selected gene clusters, 17 clusters (633 genes) were enriched
for markers of at least one lung cell type (Figure 4 and Table
2). Cluster C-1 (190 genes) was enriched for proliferating cells
including proliferating epithelial (e.g., proliferating basal),
lymphoid (e.g., proliferating T cells, proliferating natural killer
cells), and myeloid (e.g., proliferating macrophages) cell types.
Cluster C-2 (92 genes) was heterogeneous showing enrichment
for epithelial, mesenchyme, vascular endothelial, lymphoid, and
myeloid cell types. Cluster C-9 (18 genes) showed enrichment
for fibroblasts, myofibroblasts, and smooth muscle cells and
shared enrichments with clusters C-1, C-2, and C-3. Some of
the clusters were found to be specifically enriched for certain
cell types. Ionocyte cell marker22 genes, for instance, were
specific to cluster C-5 (40 genes; 12 markers); clusters C-7,
C-11, and C-13 were specifically enriched for myeloid cell
markers (Table S11).
4 Patterns 2, 100247, May 14, 2021

Gene clusters: Genotype-phenotype associations
The 35 genes clusters also showed enrichment for several
physiological and phenotypic traits that provide insights into
COVID-19 pathogenesis (Tables S12 and S13). Among the
most significantly enriched traits were respiratory system disease (clusters C-7 and C-8), asthma (C-7), autoimmune disease
(clusters C-7 and C-29), allergic rhinitis (C-7), immune system
disease (cluster C-7 and C-8), and diabetes (C-15). We also
observed risk genes associated with several inflammatory disorders such as inflammatory bowel disease and Crohn’s disease (C-7), ulcerative colitis (C-8), rheumatoid arthritis (clusters
C-7 and C-8), and ankylosing spondylitis (C-8). Apart from
elucidating the pathophysiology of COVID-19, the enriched
traits can potentially help the researchers to understand or
formulate hypotheses surrounding the long-hauler patients or
survivors. For instance, could COVID-19 be a risk factor for
autoimmune or neurodegenerative disease? A plausible mechanism could be through an overactivated innate immune
system.23–25 Both acute and delayed neurological and neuropsychiatric effects have been associated with previous viral
pandemics.26,27
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Table 1. List of differentially expressed genes (0.6 logFC; FDR p % 0.05) from the three SARS-CoV-2 infection models
Differentially expressed gene list name

No. of DEGs

GEO ID

Reference

Calu3 SARS-CoV-2: downregulated

2,272

GSE147507

Blanco-Melo et al.12

GSE150847

Riva et al.13

GSE153940

Sun et al.14

Calu3 SARS-CoV-2: upregulated

2,509

Ad5-hACE2-sensitized mouse SARS-CoV2: downregulated

2,109

Ad5-hACE2-sensitized mouse SARS-CoV2: upregulated

1,217

Vero E6 SARS-CoV-2: downregulated

953

Vero E6 SARS-CoV-2: upregulated

1,369

Overall number of unique SARS-CoV-2 DEGs: 8,286

SARS-CoV-1-targeted human protein modules
To demonstrate that the proposed workflow is disease agnostic
and to identify modules that are specific to SARS-CoV-2 infection, we implemented the same workflow for another corona virus disease caused by SARS-CoV-1. To do this, we first extracted DEGs from three different SARS-CoV-1 infection
models28–30 (Calu3 model and two mouse models), and generated the consensus DEGs. There were 699 upregulated and
1,385 downregulated genes that were differentially expressed
in at least two out of the three model systems. To generate the
SARS-CoV-1-targeted human protein modules, we used 366
host-SARS-CoV-1 protein interactions identified on the basis
of localization of viral proteins in human cells.31 Comparing the
DEGs and virus-host protein interactions of SARS-CoV-1 and
SARS-CoV-2, we found over 300 DEGs (196 upregulated and
119 downregulated) and 135 viral interactants shared, and a
large number of DEGs and protein interactions unique to each
of them. We next generated SARS-CoV-1-targeted human protein modules following the same steps as described previously
for SARS-CoV-2. We identified 68 modules that had at least
five genes (Table S14). We also computed functional and lung
cell marker enrichments for the SARS-CoV-1 modules. By
analyzing the module compositions from both of the analyses
(SARS-CoV-2 and SARS-CoV-1), we identified candidate modules that are potentially unique to each of these viruses. For
instance, cluster C-5 (40 genes) from the SARS-CoV-2 interactome contained more than 90% of its gene members (37 out of
40) from the SARS-CoV-2 consensus signature or protein interactions. Interestingly, this module was enriched for marker
genes from ionocytes and proximal ciliated cells, and several
neurodegenerative disease pathways. Similarly, 9 out of 11
genes in cluster C-15 were specific to the SARS-CoV-2 interactome, which included genes belonging to trans-synaptic
signaling and neurotrophic factor-mediated Trk receptor
signaling pathways. Among lung cell markers, proliferating
epithelial and basal cells along with transitional AT2 cell markers
were specifically enriched in our identified SARS-CoV-2 protein
modules. Likewise, we observed multiple functional pathways
(e.g., TRAIL [tumor necrosis factor-related apoptosis-inducing
ligand] signaling and IL12 [interleukin-12]-mediated signaling
pathways), biological processes (e.g., endoderm formation,
response to oxygen radical), and phenotypes (e.g., arteriosclerosis, abnormal mitochondrial crista morphology) enriched specifically in SARS-CoV-2. We also identified few protein modules
containing a significant number of genes associated with both in-

fections, potentially representing the pan-viral disease mechanisms involved (Table S14).
Meta-analysis of candidate gene modules and
enrichment network visualization
To identify the semantic concordance between the enriched cell
types, phenotypic traits, and functional terms for different gene
clusters, we next undertook meta-analysis across all the enrichments. We selected a subset of enriched terms (top ten enriched
terms from Gene Ontology—Biological Process, Reactome
pathways, mouse phenotype), cell types, and traits (both PheGenI and GWAS catalog) from each of the 35 candidate clusters
and converted them into a network layout. We used Gephi
(https://gephi.org), an open-source graph visualization platform,32 to construct and visualize the functional network. In
this dense enriched feature network (1,198 nodes and 31,065
edges, Table S15), the enriched terms (biological processes,
pathways, phenotypic traits, cell types) are represented as nodes, and two nodes are connected if they share at least one or
more of the 35 candidate gene clusters from the combined interactome map. Since subunits of a functional complex (a cluster
of, e.g., pathways, cell types, biological processes, phenotype)
work toward the same biological goal, prediction of an unknown
pathway or biological process or a phenotype as part of this
complex also allows increased confidence in the annotation of
that functional cluster. Additionally, by doing this, potential redundancies across different sources (e.g., ontology or cell types)
could be reduced, apart from enabling interpretation of the
enrichment results through intracluster and intercluster similarities of enriched terms.33 We therefore investigated the substructure of the feature network by estimating community membership modules using the Louvain algorithm34 (implemented in
Gephi). Louvain clustering is a fast, iterative algorithm that is
based on optimizing the modularity score35 and is computationally fast, efficient, and suitable for large modular networks. The
resolution parameter can be used to maintain the balance between module count and the individual cluster tightness. A
low-resolution parameter value would lead to smaller, more
tightly connected clusters and vice versa. With a resolution set
to 0.25, we found 31 communities of highly interconnected biological terms and a high modularity score of 0.672 (Figure 5).
Visualizing these functional complexes, we observed high
concordance between the functional terms, cell-type marker,
and phenotype enrichments among the candidate gene modules
(Table 3). For instance, cluster C-10 was enriched for vascular
Patterns 2, 100247, May 14, 2021 5

ll
OPEN ACCESS

Article

Figure 3. Network of consensus DEGs of SARS-CoV-2 infection models and SARS-CoV-2-host protein-protein interactions
(A) Network of 176 DEGs of three SARS-CoV-2 infection models that encode proteins interacting with SARS-CoV-2 viral proteins. The orange- and purple-colored
nodes are consensus up- or downregulated genes, respectively, while the three genes with black border (PTBP2, CEP350, and CYB5B) are part of the core set
of genes.
(B) STRING-based interaction network of consensus DEGs and SARS-CoV-2-human viral-host protein interactome.
(C–I) Example gene clusters from the consensus DEG and SARS-CoV-2-host integrated interactome. Clusters (based on MCL network clustering) shown are C-5
(C), C-9 (D), C-11 (E), C-13 (F), C-7 (G), and C-8 (H). Consensus up- and downregulated genes are in orange and purple, respectively, while the hexagonal genes
are part of the SARS-CoV-2-host protein interactome, directly interacting with the consensus DEGs.

endothelial and smooth muscle cells, platelet degranulation,
extracellular matrix, cell-substrate adhesion, and FOXP3 targets
(Figure 5). Elucidating the role of platelets in the thrombotic complications of COVID-19, two recent studies36,37 reported that
platelet hyperactivity contributes to the COVID-19-related coagulopathy. Furthermore, endothelial cell dysfunction and
impaired microcirculatory function are reported to contribute to
COVID-19 severity including venous thromboembolic disease
and multiple organ involvement.38 Foxp3 is a master regulator
of regulatory T (Treg) cells, and its expression is associated
with the immunosuppressive activity of these cells. Deficiency
of functional Treg cells caused by mutations of Foxp3 leads to
spontaneous systemic multiorgan autoinflammatory phenotypes in mice.39–42 Interestingly, CD4+CD25+FoxP3+ regulatory
T cell-based therapies are proposed for COVID-19 patient management.43 Similarly, clusters C-11 and C-13, and C-7 (Figures
3E–3G) were enriched for Toll-like receptor signaling pathway,
cytokine-cytokine receptor interaction, nuclear factor kB (NFkB) signaling, CD40 signaling, and myeloid cell types (conventional dendritic cells, mast cells, and monocytes). These clusters
showed enrichment for abnormal interleukin secretion and T cell
physiology and for several GWA loci such as granulocyte count,
inflammatory biomarker measurement, Crohn’s disease, and ulcerative colitis (Figure 5 and Table 3).
6 Patterns 2, 100247, May 14, 2021

DISCUSSION
We report a data-driven, network-based workflow to identify
gene and functional modules in a disease through joint analysis
of disease-specific and non-disease-specific data elements. By
integrating high-confidence protein-protein interactions with
disease-specific transcriptomic signatures, we first identified
protein modules that could represent perturbed states in disease. As a first pass of characterizing these modules, we
leverage existing heterogeneous omics data including different
biological processes, pathways, single-cell associations, and
genetic traits. Next, we construct a feature network using the enriched terms from different perturbed modules. These higher-order multifeature machines, or functional modules overlaid on
protein modules representing perturbed states, enable us to
identify biologically interpretable mechanisms underlying disease pathophysiology. This approach is disease agnostic and
can be applied to any disease or phenotype that has one or
more model systems with transcriptomic data.
We demonstrate the utility of our approach by undertaking a
secondary analysis of transcriptomic data from three models of
SARS-CoV-2 infection. By integrating and analyzing the transcriptomic data from COVID-19 in vitro and in vivo models in the
context of SARS-CoV-2-human virus-host protein interaction
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Figure 4. Lung single-cell marker enrichments in gene clusters from the integrated interactome of consensus DEGs of SARS-CoV2 infection models and SARS-CoV-2-host
protein-protein interactions
Marker enrichment network of 17 candidate clusters (circular nodes) that were enriched for at least
one lung cell type (rectangular nodes) marker in
human lung.

map, single-cell signatures of lung, gene annotations, and human
genotype-phenotype associations, we have identified several
functional modules that can have direct bearing on furthering
the understanding of this devastating pandemic. We also demonstrate the disease-agnostic nature of our approach through analysis of transcriptomic data from infection model systems of
another corona virus (SARS-CoV-1). Furthermore, we were able
to identify SARS-CoV-2-specific gene modules and unique functional mechanisms by comparing the results from the SARS-CoV2 with that of SARS-CoV-1 infection model systems. The various
categories of cellular functions and phenotypic traits found by
meta-analyses of SARS-CoV-2 model systems recovered both
expected and potentially novel biological insights of COVID-19.
The gene-level and higher-order feature-level clusters emerging
from the joint analysis of COVID-19- and non-COVID-19 related
data can serve as valuable resources for the scientific community
to formulate or further investigate hypotheses.
Limitations of the study
Our methodology holds certain limitations. The composition of
the protein modules is dependent on the transcriptomic signature used, and any heterogeneity in the transcriptomic data
can affect the module compositions. For instance, lack of tran-

scriptomic concordance between different
disease model systems could result in
gene or protein modules that are very
diverse. Although the Ad5-hACE2-transduced mice develop pneumonia after
infection with SARS-CoV-2 and are useful
for evaluation of vaccines and antiviral
therapies, the infection is non-lethal.14,44,45
A comparison of the transcriptomic signatures from the three model systems with
DEGs from human samples indeed
showed several genes that are uniquely
dysregulated in COVID-19 patients (GEO:
GSE152075)15 suggesting the inherent
drawbacks of current in vitro and in vivo
models of COVID-19. Newer transcriptomic signatures as and when available
from emerging refined and more representative in vitro and in vivo models of human
COVID-1946–49 can be leveraged and
analyzed using the current workflow. The
small sample size from the three disease
models used in the study is another limitation. However, we performed multiple randomized trials to demonstrate the robustness of the three transcriptomic datasets used in the study
(see experimental procedures and Figure S4). Nevertheless,
further (in vitro and in vivo) validations are warranted to test the
hypotheses arising from the current study. Recently there have
been several studies and databases reporting COVID-19-specific databases,33,50–52 which can be either used to compile
additional consensus gene sets or for further functional characterization of the modules discovered in the current study.
The STRING-based PPI network data suffer from incompleteness and a certain degree of noise. There are no set standards
for the optimal STRING interaction score cutoff. Furthermore,
although Markov clustering is recommended for module detection,53 there are no specific guidelines for inflation factor
threshold nor for the functional annotation of modules. Nevertheless, to overcome some of these limitations, we used a very stringent cutoff score of 0.9 for STRING interactions and selected 2.5
(default) as the MCL inflation factor. The cluster composition can
also vary depending on the clustering algorithm and parameters.
Additionally, the choice of external (non-disease) data elements
is likely dependent on the disease or phenotype being studied.
For instance, to identify cancer driver modules, DNA-level alterations (e.g., variants, copy number alterations) and RNA-level
regulation data have been proved to be more effective.54 To
Patterns 2, 100247, May 14, 2021 7
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Table 2. Candidate clusters in SARS-CoV-2 DEG and interaction
map along with their enriched lung cell types
Cluster

Enriched cell markers

C-1 (190 genes)

proliferating natural killer/T cells,
proliferating basal, proliferating
macrophage, adventitial fibroblasts,
alveolar epithelial type 1

C-2 (91 genes)

proliferating epithelial, ciliated, proliferating
macrophage, classical monocytes, alveolar
epithelial type 1, adventitial fibroblasts

C-3 (81 genes)

adventitial fibroblasts, lipofibroblasts,
bronchial vessel 2, classical monocytes,
mast cells

C-4 (73 genes)

ciliated, capillary endothelial cells

C-5 (40 genes)

ionocytes, proximal ciliated

C-6 (34 genes)

bronchial vessel 1, lipofibroblasts,
mesothelial

C-7 (20 genes)

dendritic cells, mast cells, classical
monocytes

C-9 (18 genes)

alveolar epithelial type 1, fibroblasts, basal,
myofibroblasts, smooth muscle cells

C-10 (17 genes)

lymphatic, peribronchial, arterial

C-11 (15 genes)

dendritic, mast cells

C-13 (14 genes)

classical monocytes

C-18 (10 genes)

proliferating epithelial, proliferating T cells

C-22 (8 genes)

ionocytes, macrophages, proliferating
T cells

C-30 (6 genes)

proliferating T cells

C-31 (6 genes)

Arteries

C-34 (5 genes)

plasma cells

C-35 (5 genes)

plasma cells

Clusters with R5 genes enriched for at least one human lung cell type are
shown. For a complete list of clusters and their enriched cell types see Table S9 and Table S11, respectively.

alleviate the issues related to noise and incompleteness in PPI
networks, graph neural network implementations, which are
robust to structural noise in input networks, could be useful.
Adding the expression profiles as node features could also be
an efficient way to introduce disease-specific transcriptomics
data into the network-based analysis. Using attention-based implementations allows us to assign dynamic similarity weights to
nodes (proteins) based on the similarity of their neighborhoodaggregated features. Additionally, we also plan to explore mechanisms that can integrate heterogeneous human transcriptomic
data coming from distinct sources including nasopharyngeal
swabs and peripheral blood mononuclear cells. In summary,
bringing together a consensus gene signature from multiple disease model systems and analyzing it jointly with other omics
data provide a basis for addressing several basic and translational research questions for existing and emerging diseases.
EXPERIMENTAL PROCEDURES
Resource availability
Lead contact
Further information and requests should be directed to and will be fulfilled by
the lead contact, Anil G. Jegga (anil.jegga@cchmc.org).
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Materials availability
This study did not generate any unique reagents.
Data and code availability
All data generated or analyzed during this study are included in this article and
its supplemental information files. Also, the code for reproducing our result
files and figures is accessible publicly at https://github.com/
SudhirGhandikota/COVID19_secondary_analysis. Additional supplemental
items are available Mendeley Data at https://doi.org/10.17632/3cwxv9swkc.1.
SARS-CoV-2 infection models: Differentially expressed genes
We used transcriptomic data from human (Calu-3) and non-human primate
(VeroE6) cell lines, and from a mouse model (Ad5-hACE2) of SARS-CoV-2
infection (Table 1). The SARS-CoV-2 infection triggered transcriptome in
Calu-3 cell lines (GSE147507)12 is based on six samples with three each of
mock treated or infected with SARS-CoV-2. The second transcriptome signature is based on mRNA profiles of control and 24-h post-SARS-CoV-2-infection (USA-WA1/2020, multiplicity of infection = 0.3) in Vero E6 cells (kidney
epithelial cells extracted from an African green monkey (GEO:
GSE153940).13 The third dataset is from a mouse model using Ad5-hACE2sensitized mice (GEO: GSE150847)14 that develop pneumonia after infection
with SARS-CoV-2, overcoming the natural resistance of mice to the infection.
Raw data from GEO: GSE147507,12 GSE153940,13 and GSE15084714 were
obtained and analyzed using the Computational Suite for Bioinformatics and
Biology (CSBB v3.0).55 The raw data were downloaded from NCBI Sequence
Read Archive (ProcessPublicData module), and the technical replicates were
merged for individual samples before processing them (Process-RNASeq_SingleEnd module). Quality checks56 and quality trimming57 were conducted
prior to the transcript mapping/quantification step using the RSEM package.58
Raw counts and transcripts per million were generated for all samples for
further downstream analysis. Within each sample series, differential expression (DE) analysis was carried out based on treatment versus mock samples
using the CSBB-Shiny server.19 RUVSeq59 was used to remove potential variation and sequencing effects from the data before performing DE analysis using edgeR.60 DEGs were obtained by applying a 1.5-fold change threshold
(i.e., log 2 FC R0:6 or log 2 FC% 0:6) and a p value (false discovery rate
[FDR] correction) of <0.05. For obtaining the human ortholog genes for mouse
(Mus musculus) and green monkey (Chlorocebus sabaeus), we used ortholog
mappings from the NCBI’s HomoloGene.
SARS-CoV-2-human virus-host protein-protein interactions data
The SARS-CoV-2-human virus-host protein-protein interaction data included
a set of 332 human proteins involved in assembly and trafficking of RNA viruses and shown recently through affinity purification and by mass spectrometry to interact physically with 26 of 29 SARS-CoV-2 structural proteins.18
These are in addition to the SARS-CoV-2 entry receptor ACE2, and SARSCoV-2 entry-associated proteases, namely, TMPRSS2, CTSB, and CTSL.
Consensus DEGs: Robustness tests
To test the robustness of DEGs and the consensus transcriptome from the
three input disease models used in our framework, we performed four different
randomized permutation tests. In the first set of experiments, we randomly
permuted the phenotype labels in each individual study, identified the DEGs,
and tried to obtain the consensus signature (genes that are differentially expressed in two or more studies). We repeated this for 1,000 iterations and
observed that the number of DEGs found in each disease model is significantly
less than the actual counts (Figure S4A). Consequently, we did not identify a
consensus signature in any of the randomized trials due to the low DEG
counts. Given the small sample sizes, the same phenotype combinations
were repeated a few times in our trials. In the second set of experiments, we
permutated the labels in two of the three studies and reused the original
DEGs from the third study. We again repeated this process 1,000 times for
each combination (3,000 random trials in total) and computed the consensus
DEGs in each case. Here too we did not observe a significant number of
consensus DEGs (Figure S4B) in any of our trials (<25 genes).
Our next set of experiments was designed to validate the level of connectivity observed among the SARS-CoV-2 consensus DEGs along with their interactions with the SARS-CoV-2 virus-host interactants. To achieve this, we
first generated DEG sets in each individual study by randomly picking the
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Figure 5. Network visualization of the results from joint analysis of multiple annotations from the 35 gene clusters
Network representation of clustered enriched terms from functional enrichment analysis (multiple annotations such as Gene Ontology, pathways, lung cell types,
and GWA loci) of candidate gene clusters from the integrated consensus DEG and SARS-CoV-2-host interacting protein network. Enriched terms from different
annotation categories are represented as nodes, while the edges represent shared gene clusters (35 select gene clusters). Representative terms in some of the
clustered functional modules are listed on the left side with different font colors representing different annotation categories (blue, biological processes/pathways; green, phenotype; red, cell type; black, GWA trait). The underlying gene clusters (35 select gene clusters) for each of the clustered functional terms are
also shown.

same number of genes as obtained originally (Table 1) and identified the
consensus signature from among them. As is the case in our earlier experiments, we observed that the counts of consensus DEGs in our random trials
are significantly lower than the observed gene sets (Figure S4C). These
consensus genes were then combined with the SARS-CoV-2-human virushost interactome (336 genes), and the integrated gene set was tested for
enrichment of protein-protein interactions from STRING.19 We repeated
these two independent steps 1,000 different times and plotted the enrichment p values in each case (Figure S4C). On average, the consensus DEG
counts from our random tests were around 300 genes while the empirical
p values were less significant than the observed level (p < 1.0 3 10 16).
Although we found statistically significant (p % 0.05) PPI enrichments in
some of our trials, we hypothesized that these might be driven by the 336
SARS-CoV-2 interactants. Therefore, we tried to test this in our final set of
experiments by randomly picking 1,803 genes (1,467 conserved + 336
SARS-CoV-2 interactants) and then checked for their PPI enrichments.
This time, we observed fewer significant enrichments (p % 0.05) among
1,000 independent trials (Figure S4D). We also found that the average local
clustering coefficient values (from STRING) in each trial were smaller than
the actual value (0.42) (Figure S4D). In all our experiments, we used the
STRING API (https://string-db.org/help/api/) to compute PPI enrichments
and to retrieve the clustering coefficient scores.
Functional and human lung cell markers enrichment analysis
Functional enrichment for Gene Ontology biological processes, mouse phenotypes, pathways, and 4,872 immunologic61 and 50 hallmark62 gene sets from
MSigDB63 was done using the ToppGene suite64 while the pathway enrichment analysis using the Elsevier Pathway Collection was done using Enrichr.65
Additionally, to detect specific cell types potentially perturbed or affected in

COVID-19, we intersected the DEGs and gene clusters from SARS-CoV-2
infection models with cell-type markers (FDR p % 0.05; logFC R 0.5) from
normal adult human lung.20–22
Genome-wide association trait enrichment analysis
For gene and phenotype trait association analysis, we used data from the
NCBI’s Phenotype-Genotype Integrator (PheGenI)16 and the NHGRI-EBI
GWAS catalog.17 We used significant (1 3 10 5) vulnerability loci of various human physiological traits, excluding all intergenic variants. Additionally, we also
included child trait associations for the mapped traits from the GWAS catalog.
The child terms for each trait were obtained by parsing the experimental factor
ontology hierarchy.66 We applied Fisher’s exact test to find the enrichments.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
patter.2021.100247.
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Table 3. Enriched functional terms shared among the 35 candidate gene clusters from the integrated network of consensus DEGs of the
three SARS-CoV-2 infection models and the SARS-CoV-2-host protein interaction map
Cluster

Enriched functional terms

C-7 and C-29

atypical NF-kB pathway; autoimmune disease

C-2, C-7,
and C11

apoptotic mitochondrial changes; positive regulation of apoptotic process by virus; PAR1-mediated thrombin
signaling events; ceramide signaling pathway; abnormal melanocyte morphology; abnormal splenocyte apoptosis;
leukocyte count

C-8 and C-19

canonical NF-kB pathway; regulation of cytoplasmic translation

C-2, C-7, C-3,
and C-25

genes regulated by NF-kB; circadian rhythm—mammal; genes upregulated in regulatory T (FOXP3+) cells from
B6 mice

C-18, C-2,
and C-5

proliferating basal; proliferating macrophages; DNA replication; E2F transcription factor network

C-13, C-7,
and C-2

OLR1+ classical monocytes; neutrophil activation; b3 integrin cell surface interactions; liver inflammation; increased
susceptibility to bacterial infection

C-1, C-7,
and C-10

dendritic cells; proliferating macrophages; innate immune response; increased susceptibility to infection; platelet
function tests; immune effector process

C-2 and C-3

adventitial fibroblasts; mesothelial; intermediate monocytes; mRNA metabolic process; abnormal heart ventricle
morphology; genes upregulated in response to low oxygen levels

C-21

decreased coronary flow rate; abnormal renal vascular resistance; airway wall thickness measurement; orotic acid
measurement

C-23 and C-35

plasma cells; peptide metabolic process; translational initiation; regulation of translation; mitochondrial gene
expression and translation

C-8 and C-2

apoptosis; activation of innate immune response; NOD-like receptor signaling pathway; Toll-like receptor signaling
pathway; TNF receptor signaling pathway; immune system disease; respiratory system disease

C-7

NF-kB signaling; response to cytokine; signal transduction through IL1R; IL23-mediated signaling events; genes
related to CD40 signaling; T cell receptor signaling pathway; IL12-mediated signaling; abnormal interleukin secretion;
abnormal T cell physiology; mast cell/basophil type 2; cDC1; Langerhans dendritic cells; cDC2; ulcerative colitis;
Crohn’s disease; inflammatory biomarker measurement; asthma; hypothyroidism; granulocyte count

C-9 and C-2

cell-substrate adhesion; extracellular matrix; genes encoding collagen proteins; endothelial cells; AT1; fibroblasts;
smooth muscle cells; myofibroblasts; intracerebral hemorrhage; Marfan syndrome; b-blocking agent use
measurement

C-10 and C-2

genes encoding extracellular matrix; arterial vascular endothelial cells; smooth muscle cells; platelet degranulation;
membrane fusion; vesicle fusion; VEGF and VEGFR signaling network

C-5, C-12,
and C-28

mitochondrion organization; mitochondrion transport; oxidative phosphorylation; ATP biosynthesis; abnormal
mitochondrial crista morphology; Alzheimer’s; Parkinson’s

C-16 and C-17

fatty acid catabolic process; peroxisome organization; lipid oxidation; propanoate metabolism; PPAR signaling
pathway; abnormal lipid level; blood metabolite measurement

The shared terms (biological processes, pathways, cell types, and phenotypic traits) are found through meta-analysis of the enriched terms from different
annotation categories for the 35 gene clusters. The complete network along with all enriched terms and cluster details are presented in Table S10. IL,
interleukin; cDC1 and cDC2, conventional dendritic cell types 1 and 2; PPAR, peroxisome proliferator-activated receptor; TNF, tumor necrosis factor;
VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
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